Transplant in ALL after CAR T-cells & amp; the role of MRD
With the recent influx of targeted, highly effective novel agents to the field of acute lymphoblastic leukemia (ALL), there is some uncertainty surrounding the role of aggressive treatments like stem ...
Author: VJHemOnc
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
ASCT remains at the forefront of multiple myeloma therapy
Despite recent advances in drug development, autologous stem cell transplant (ASCT) is still, to date, the most effective treatment for multiple myeloma (MM). Speaking from the 1st European Myeloma Ne...
Author: VJHemOnc
Added: 07/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 26, 2018 Category: Cancer & Oncology Source Type: podcasts
Redundancy of age restrictions for MM treatment
Autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients has often been capped at 65 years of age. However, Mohamad Mohty, MD, PhD, of the University Pierre & Marie Curie, Pa...
Author: VJHemOnc
Added: 07/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Refinements in MM treatment: a dynamic, ever-evolving field
Autologous stem cell transplantation is here to stay for multiple myeloma (MM). However, once a treatment has been developed, there is no reason why it should not be improved. Here, Mohamad Mohty, MD,...
Author: VJHemOnc
Added: 07/25/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 25, 2018 Category: Cancer & Oncology Source Type: podcasts
Brentuximab vedotin plus ESHAP: complete remission in R/R Hodgkin lymphoma
The combination of brentuximab vedotin and ESHAP has had positive results when used prior to autologous stem cell transplant in patients with refractory/relapsed Hodgkin lymphoma. Here, Ramon Garcia-S...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
Haploidentical vs. unrelated transplants in DLBCL
Stem cell transplants are one of the most well-studied and effective therapies for blood cancers. In this video, Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Duran I Reynals Hospital, B...
Author: VJHemOnc
Added: 07/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2018 Category: Cancer & Oncology Source Type: podcasts
The potential impact of gilteritinib in patients with FLT3-ITD AML?
Eunice Wang, MD, shares the potential impact of gilteritinib as maintenance therapy after allogenic hematopoietic stem cell transplantation in patients with FLT3-ITD acute myeloid leukemia (AML)
Author: obr
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Stem cell therapies promising for Hodgkin lymphoma
Trends in the use of stem cell transplantation in relapsed and refractory Hodgkin lymphoma are currently being studied by the European Society for Blood and Marrow Transplantation (EBMT). In this inte...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD in AML: prognoses, transplant and treatment planning
Measurable residual disease (MRD) has become a crucial part of treatment planning and prognosis construction in many hematological diseases; however, in acute myeloid leukemia (AML), heterogeneity of ...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Fecal transplants as salvage therapy for acute refractory GvHD
Allogenic stem cell transplants are the only curative therapy available for several hematological diseases; however, graft-versus-host disease (GvHD) is a common complication of this procedure. The ac...
Author: VJHemOnc
Added: 07/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Reflections on an excellent EBMT 2018
The 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, proved to be an exciting congress with >5,000 delegates in attendance - the highest attenda...
Author: VJHemOnc
Added: 07/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Using MRD to inform allocation of stem cell transplants in ALL and AML
Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, spoke to us at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, about how measurable residual ...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Incorporating novel therapies into frontline ALL treatment
Eliminating high toxicity, invasive treatments like chemotherapy and stem cell transplant is a goal of acute lymphoblastic leukemia (ALL) research. Here, Oliver Ottmann, MD, FRCPath, of Cardiff Univer...
Author: VJHemOnc
Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts
Biomarkers for GvHD risk in allo-SCT
Allogeneic stem cell transplantation (allo-SCT) is the only curative option for many patients with hematological malignancies. It is therefore crucial that allo-SCT is utilized appropriately to optimi...
Author: VJHemOnc
Added: 07/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Transplantation clinical trial network to build available prospective studies on AML
With the remarkable success of the US Bone Marrow Transplant Clinical Trials Network (BMT CNT), founded by Mary Horowitz, in running successful prospective transplantation clinical trials, it is only ...
Author: VJHemOnc
Added: 07/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 16, 2018 Category: Cancer & Oncology Source Type: podcasts
